August 21, 2006 -- Ranbaxy Labs is ready to buy a Russian generic drug manufacturer, Akrikhin, for $100 million; a flu vaccine from Dynavax has the potential to be a universial flu vaccine; Oscient completed its acquisition of US rights to cholesterol drug Antara; Schering-Plough withdrew its application for approval of garenoxacin, an antibiotic; Teva won Canadian approval for Azilect, an oral drug for Parkinson’s disease; Celera was given an NIH grant to develop a test for bird flu; Nabi will pay up to $18 million for manufacturing technology; Introgen discovered biomarkers that predict the efficacy of cancer drug Advexin; NICE decided to play not-nice with Genentech and ImClone, refusing to approve their colorectal cancer drugs because of cost. The Centient Biotech 200™ fell 13 points to 3693.02, a slide of .36%. More details...
